ReviewDigestive diseases and sciences2026
Focal Pancreatic Parenchymal Atrophy and Delayed Enhancement in Early Pancreatic Ductal Adenocarcinoma: A Narrative Review of Pathologic Basis, Diagnostic Pitfalls, and Evidence Limitations.
Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early pancreatic ductal adenocarcinoma (PDAC), including carcinoma in situ (CIS)/high-grade pancreatic intraepithelial neoplasia (PanIN) and very small invasive tumors, is increasingly recognized, but the significance of pancreatic parenchymal atrophy and delayed enhancement remains unsettled. This narrative review summarizes their pathological basis, technical determinants, observer variability, differential diagnoses, and evidence limitations across computed tomography (CT), magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasonography (EUS), and regionally variable pancreatic duct-oriented cytology pathways. Parenchymal atrophy should be distinguished from ductal abnormalities such as focal main pancreatic duct stenosis and perilesional branch-duct dilation, which depend heavily on technically optimized MRCP, including high-quality two-dimensional MRCP. Atrophy is a morphologic phenotype with heterogeneous substrates, whereas delayed enhancement more often reflects fibrosis-rich or inflammatory change and is not specific for PDAC, because focal autoimmune pancreatitis may show similar delayed enhancement. Reported prevalence and diagnostic value vary according to cohort spectrum, modality, phase definition, reader blinding, cytologic verification, and hindsight bias. Current evidence supports these signs as context-dependent clues, not diagnostic thresholds or management algorithms. Prospective pathology-linked studies with standardized protocols are needed.
Indexed as
Identifiers
42440005What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.